Anti-programmed death ligand-1 (PD-L1) and anti-programmed death protein 1 (PD-1) antibody immunotherapy has already been used in the treatment of metastatic SCLC and has yielded encouraging therapeutic results (12). The gene discussed is CD274; the disease is small cell lung carcinoma.